Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(83.3%)
Phase 1
1(16.7%)
6Total
N/A(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06245421Not ApplicableCompleted

Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness

Role: lead

NCT06607237Not ApplicableCompleted

Evaluation of Safety and Efficacy of DM-28 for Treatment of Moderate to Severe Ocular Dryness

Role: lead

NCT05191771Not ApplicableUnknown

Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction

Role: lead

NCT05006768Phase 1Completed

Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)

Role: collaborator

NCT03645850Not ApplicableUnknown

Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness

Role: lead

NCT03517748Not ApplicableCompleted

Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness

Role: lead

All 6 trials loaded